Overview

A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.

Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if using Eprex, to maintain hemoglobin within the normal range, will prevent or delay the progression of left ventricular mass growth.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen-Ortho Inc., Canada
Treatments:
Epoetin Alfa